Part I: Biotech Deals — Creating Optimal Licensing and Partnering Arrangements

Please join Arnold & Porter for Part I of our in-person series designed for legal and business leaders at biotechnology companies focused on optimizing their licensing and partnering.

This program will take the form of a presentation and boardroom-style discussion focused on the strategic question of whether to license an asset. We will explore key considerations that inform licensing and partnering strategies, including:

• Out-licensing versus strategic alternatives
• Transaction structuring priorities, including diligence focus
• Intellectual property and exclusivity protections
• Regulatory pathways considerations
• Antitrust and Hart-Scott-Rodino Act compliance issues
• Tariff and pricing dynamics (including IRA and MFN considerations)

We look forward to a thoughtful and engaging discussion!

Program Alert

We hope you’ll save Wednesday, September 16 for the second program in this series where we’ll explore practical approaches to navigating and resolving complex disputes that may arise when a licensing partnership begins to unravel.